Patient Characteristics | Â |
---|---|
Patients, n (%) | 34 (6.8) |
Sex, female, n (%) | 20 (58.8) |
Duration between onset of arthritis and uveitis, years, mean ± SD | 1.8 ± 1.9 |
 oJIA | 1.9 ± 1.8 |
 ERA | 1.7 ± 2.1 |
 Poly JIA, RF– | 1.8 ± 3.0 |
Onset of uveitis after JIA diagnosis,a years, n (%) | |
 0–1 | 13 (38.2) |
 1–2 | 4 (11.8) |
 2–3 | 5 (14.7) |
  > 3 | 9 (26.5) |
Affected eye,b n (%) | |
 Right only | 5 (17.2) |
 Left only | 8 (27.6) |
 Both | 16 (55.2) |
Localization of uveitis,c n (%) | |
 Anterior | 19 (76) |
 Intermediate | 2 (8) |
 Posterior | 2 (8) |
 Panuveitis | 2 (8) |
Categories of JIA/sex distribution, n (%) [female % within n] | |
 oJIA | 25 (73.5) [64] |
 poJIA | 20 (58.8) [65] |
 eoJIA | 5 (14.7) [60] |
 ERA | 6 (17.7) [9] |
 Poly JIA, RF– | 3 (8.8) [100] |
ANA positivity, n/N (%) | 22/34 (64.7) |
HLA-B27 positivity, n/N (%) | 3/10 (30) |
Systemic treatments initiated after the diagnosis of uveitis, n (%) | |
 Methotrexate | 6 (17.6) |
 Azathioprine | 4 (11.8) |
 Sulfasalazine | 4 (11.8) |
 TNF-alpha inhibitors | 13 (38.2) |
 Tocilizumab | 3 (8.8) |
Complications, n (%) | 5 (14.7) |
 Cataract | 4 (11.8) |
 Band keratopathy | 1 (2.9) |